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S rq wThis study was performed to determine the changes in pulnonary function in patients randomised
to receive treatment with four cycles of bleomycin, etoposide and cisplatin (BEP) (27 patients) or with four
cyces of etoposide and cisplatin (EP) (27 patiets) for ssemnated non-semiomatous lar ncmer. Tlis
enabled us to establish whether efects other than those due to bleomycin determined the detrimental effects of
BEP on hmg function asssNNF ents. Slow inpiratory vital capacity (VC), the transfer factor of the hmgs for
carbon monoxide (Tun), the diffusing capacity of the alveolo-capillary membrane (D.), the pulnonary
capillary blood volume (Vj) and the tramnsfer factor ofthe hmgs for carbon monoxide per unit ahliar vohlme
(Km) wr determined before and at 3 }wk intervals during chemotherapy. Both groups, similar in terms of
factors that may influe pulmonary function, showed during therapy a sigfant decreas in To compared
with the pretreatment vahlc. Only at the end of the therapy was a sificant diffen in T between both
groups observed. Jdiminished also significantly in both groups during treatment, but differences between
both groups wem not sen. VC and V, decreased in patiets reciving BEP but reMained constant during
treatment with EP. It can be cocxed that the D., Kco, and the widely used TLCO are not suitable parameters
to monitor speifically pulmonary toxicty induced by bleomycin as part of a mulidrug regimen. However, VC
and V, appear to be proper lung function asseNssents which reflect spcifically alterations induced by
bloomycin.
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The standard chemotherapy for patients with diinated
tsticular germ cell tumours consists of a combination of
bleomycin, etoposide and cisplatin (BEP) (Williams et al.,
1987), lading to an overall 5 year survival of these patients
of 87% (Dearnaley et al., 1991). A major disadvantage of
this treatment is the occurrnce of bleomycin-induced
pneumonitis (BIP). The reported inc of this toxicity
varies from 0 to 46% of the patients receiving a bleomycin-
containing therapy (De Lena et al., 1972; Van Bameveld et
al., 1984; Williams et al., 1987; Juls-Elysee et al., 1990;
Dernaley et al., 1991; Osanto et al., 1992). Fatal BIP occurs
in approximately 3% of patients treated with bleomycin
(Levi et al., 1993). However, bleomycin nowadays is only
used as part of a multidrug chemotherapeutic reilmen, and
so the impact of bleomycin alone on lung function is not
known.
The transfer factor of the lungs for carbon monoxide
(TLC) is assumed to reflect alterations in the lungs caused by
bleomycin, and therefore TLCO has become a tool to detect
BIP (Comis, 1992). The value of TLo is determined by the
diffsing capacity of the alveolo-capillary membrane for
carbon monoxide (D.) and the pulmonary capllary blood
volume (Vc). Previously, we have shown that determination
of TLco, and espeially of the two components of TLcD, D.,
and Vc, and determination of the slow inspiratory vital
capacity (VC) are the best indicators of pulnonary toxicity
during a bleomycin-containing treatment for diminated
testicular cancer (Luursema et al., 1983; Van Barneveld et al.,
1985). Moreover, we showed that when BIP occurs it is
completely reversible with time (Van Barneveld et al.,
1987).
In recent years, different prognostic systems have been
developed in order to predict the outcome of therapy in
patients with diminated tesicular germ cell tumours.
Based on these systems, patients can be divided into groups
with a good or a poor prognosis. For the treatment of
patients with a good prognosis less toxic chemotherapy
rgmens are studied. Thefore, the EORTC Genito-Urinary
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Tract Group started a randomised study comparing BEP
with etoposide and cisplatin (EP) in good-prognosis patients
(Stoter el al., 1987). We have evaluated as a side study the
influens of BEP as well as of EP on the pulmonary func-
tion parameters mentioned above and the transfer factor of
the lungs for carbon monoxide per unit alwolar volume
(Kco). This gave us the opportunity to study the detrimental
effects of bleomycin and the other drugs of the combination
separately and to establish whether the lung function assess-
ments eamined are suitable parameters which reflect
spefically changes induced by bleomycin.
Ptes as~hI
Fifty-four patients with low-volume metastases of a dissem-
inated non-seminomatous tumour of the testis were random-
ised. Low-volume metastases were defined as infradiaphrag-
matic nodal disease smaller than 5 cm diameter, iastinal
nodal disease smaler than 5 cm diameter, supraclaviular
nodal disease smaler than 5 cm diameter or lung metastases
four or less in number and smaller than 2 cm in dia-
meter.
Twenty-seven patients, mean age 31 years (range 21-44),
were treated with four cycles of BEP, consisting of cisplatin
20mgm-2 i.v. on days 1-5, every 3 weeks, etoposide
120 mgm-2 i.v. on days 1, 3 and 5 every 3 weeks and
bleomycin 30 mg dissolved in 100 ml of 0.9% sodium
chloride intravenously infused over 15 min on day 2 and
thereafter weekly for 12 weeks.
Twenty-seven patients, mean age 31 years (range 17-51),
were treated with four cycles of EP, consisting of cisplatin
and etoposide only.
Patient records were checked for factors known to
influence the lung function parameters examined, such as
previous pulmonary disease (e.g. asthma) and smoking
habits. Before the start of the chemotherapy and at 3 week
intervals during treatment, lung function tests were carrid
out.
Slow inspiratory vital capacity (VC) was measured with a
standard water-sealed spirometer. TLco was masured with
the single-breath technique of Krogh et al. (1914) modifiedLingfb -i^g u d mcdvi inr
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by Ogive et al. (1957) and Cotes (1979). D. and Vc were
determined by measuring TLo at two different oxygen con-
centrations (18.4% and 88.0%). The calculations were per-
formed according to the equation given by Roughton et al.
(1957). All measurements were carried out in duplicate. The
values of T! have been corrected for the haemoglobin
concentration according to Cotes (1979) in order to obtain a
value of TLOO under standard conditions. The alveolar
volume (VA) was caculated from the inspiratory and expira-
tory helium concentrations measured during the determina-
tion of TLc. The transfer factor of the lungs for carbon
monoxide per unit alveolar volume (Kco) was obtaied by
dividing the TLa,, correted for haemoglobin concentration,
by the alveolar vohlme. Lung functions were expressed as a
percentage of the predicted value according to the regression
equations given by Cotes (1979).
BIP was defined as a clnical syndrome featuring dry
cough, exertional dyspnoea, dyspnoea at rest, tachypnoea,
fever and cyanosis. On chest radiography, BIP was revealed
by a fine recular bibasilar infiltrate, an alveolar interstitial
bibasilar infiltrate, progressive lower lobe involvement or
lobar consolidation (Comis, 1992). Bleomycin was discon-
tinued in those patients developing BIP. Changes in lung
function parameters were not used to reduce bleomycin
dosages, nor was dose reduction allowed for any other
reason. Statistical analysis to compare changes in lung func-
tions to pretreatment values was performed by analysis of
variance (ANOVA) in a repeated measurement design. For
analysing differences in lung and renal functions between
both therapies, two-tailed unpaired Student t-tests were used.
P-values below 0.05 were considered to be significant.
value increased until week 12 (P<O.001). A significnt differ-
ence between both groups was only observed in week 12
(P<0.01) when the decrease in the BEP group was most
prominent.
The pulmonary capillary blood volume (Vc), one of the
components of the TIco, did not change in the EP group
during treatment (Figure 2). However, in the BEP group the
Vc decreased significantly from week 9 onwards (P<0.05).
Compared with the EP group, the Vc in the BEP group was
significntly lower in weeks 9 and 12 (P<0.05).
Figure 3 shows that the other component of TLCO, the
diffuing capacity of the alveolo-capillary membrane (D.),
diminished in both groups. Compared with the pretreatment
value, this decrease was significnt in the BEP group from
weeks 9 to 12 (P<O.01) and in the EP group from week 6
until the end (P<O.O01). The reduction in D. seemed to
lessen in the EP group during the last 3 weeks of treatment.
D. values did not differ significantly between the groups.
The course of Koo, T,^ corrected for differences in
alveolar volume (VA), is depicted in Figure 4. KO decreased
in the BEP group as well as in the EP group, and this decline
was significant in both groups from weeks 3 to 12 (week 3,
P<0.05; weeks 6-12, P<0.001). No difference was observed
between therapies.
The VC had a tendency to increase during treatment with
EP, but this increase did not reach signifiCance (Figuye 5). In
the BEP group, however, VC increased signifintly from the
start to week 3 of treatment (P<0.05). Thereafter, the VC
declined, and this was sign t in week 12 compared with
the pretreatment value (P<O.O1). Only in week 12 was a
significant difference in VC between both groups observed
(P<O.O1).
Resdks
The characteristics of the patients are summarised in Table I.
Factors that may iuence the course of the pulmonary
functions such as age, smoking habits and changes in renal
function (creatinine dcance) during treatment did not differ
betlwen both groups of patients. The incidence of prior lung
diseas was negligible, and no patients reived oxygen
therapy or previous anti-cancer therapy. In the group treated
with BEP, there were more patients with hmg metasa
However, preteatment values of lung function did not differ
between patients with or without lung metaa (rlts not
shown).
Of the 27 patients treated with BEP, three developed BIP,
all in the fourth cycle of therapy (weeks 9-12). These
patients were not given the twelfth administraion of
bleomycin and so receved 330mg of bleomycin in total, in
contrast to the other patients in the BEP group, who received
360 mg in total. The lung function parameters of the patients
who developed BIP did not differ signiantly from the
other patients treated with BEP (results not shown). Among
the patients who received EP, none developed pulmonary
symptoms.
In both the BEP group and the EP group, TLco decreased
compared with pretreatment values (Figure 1). This decline
was signint in both groups in week 6 (P<0.01). This
decline continued, and the difference from the pretreatment
Table I Patients' characteristics
BEP EP
No. ofpatients 27 27
Mean age in years (range) 31 (21-44) 31 (17-51)
Lung metastases (no. ofpatients) 8 3
Smoking history (no. ofpatients) 9 11
Mean creatnin clearance in mlmmn'
(s.d.) before cycle
1 145 (26) 136 (24)
2 143 (26) 132 (27)
3 139 (26) 131 (29)
4 126 (26) 128 (20)
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0
Week
Fuwe Changes in TLco in patients treated with BEP (-) or
EP (A) (per cent mean difference from pretreatment value). Error
bars represent the standard deviation.
0U..l
Week
Fgwe 2 Chang in Vc in patients treated with BEP (U) or EP
(A) (per cent mean differen from pretratment vahle). Error
bars rersent the standard deviation.
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Week
Fugwe 3 Changes inD. in patients treated with BEP (-) or EP
(A) (per cent mean differe from pretratment value). Error
bars represent the standard deviation.
0
-
Week
Fwe 4 Changes in Koo in patients treated with BEP (U) or
EP (A) (per cent mean difference from pretreatment value). Error
bars represent the standard deviation.
0
Week
Fngwe 5 Changes in VC in patients treated with BEP (U) or EP
(A) (per cent mean differewe from preteatment value). Error
bars represent the standard deviation.
Although bleomycin has been successfl as part of a com-
bination with etoposide or vinblasti and cisplatin against
germ cell cancer, bleomycin is suspected of inducing pul-
monary toxicity. To avoid this toxicity, the EORTC Genito-
Urinary Tract Group started a randomised study to compare
the anti-tumour efficacy and toxicity of treatment with BEP
compared with the probably less toxic treatment with EP
(Stoter et al., 1987). We performed a side study to monitor
the changes in vital capacity (VC), transfer factor of the
lungs for arbon monoxide (Tico), the diffusing capacity of
the alveolo-capllary membrane (D>, the pulmonary capil-
lary blood volume (Vc) and the transfer factor for carbon
monoxide per unit alveolar volume (Kc) during treatment
with BEP or EP in all patients entering this study in our
centre.
Based on histological changes in animls observed after
administration of bleomycin (Adamson et al., 1974), it was
assumed that the reduction in TLO observed during treat-
ment of patients with bleomycn-containing combination
chemotherapy was predominantly caused by the bleomycin.
Moreover, a decrease in TLC below the 60% pretreatment
value has been used as an argument to reduce or to discon-
tinue the doses of bleomycin nis during treatment
(Comis et al., 1979; Ginsberg et al., 1982). However, bleo-
mycin is used not as a single agent but almost always in
combination with other chemotherapeutic drugs. Thus,
changes in TLCO during treatment may also be caused by the
other agents used such as etoposide/vinblastin and cis-
platin.
The change in TLoC found in this study during treatment
with BEP is 'consistent with previous studies of bleomycin-
containing therapy performed by us and others (Comis et al.,
1979; Luursema et al., 1983; Sorensen et al., 1985; Van
Barneveld et al., 1985; White et al., 1987; Hansen et al., 1989;
Wolkowicz et al., 1992). However, our study reveals that this
decli is not caused only by bleomycin because the TLCO
also decreased in patients treated with EP only. Moreover,
the continuing decrease in TLC during treatment with BEP
and EP only differs at the very end of therapy when the
decli in T.c is most pronounced in the BEP group and
reached significnt difference. This difference is probably due
to a reduction in the alveolar volume (VA) in the BEP group
compared with the EP group, because no obvious differences
are observed between the groups when the TLO is corrected
for changes in VA by applying the Kco. The decline in TLjO in
the EP group is accompanied by a decrease in D., while Vc
remains constant. Thus, it can be conduded that the reduc-
tion in TLc, is caused by alterations in the alveolo-capilary
membrane induced by etoposide and/or cisplatin and that
these two agents do not have any effect on the Vc. How
etoposide and/or cisplatin induce these changes which lead to
decases in both D. and TLCO is not known. Cisplatin has
not previously been reported to induce such changes in lung
fumctions, and etoposide-related pulmonary toxicity is only
very sporadically described (Zimmerman et al., 1984). In
contrast, capillary alterations caused by these agents are well
known and recently reviewed by Doll et al. (1992).
Because the decrease in D. is also observed in the BEP
group, it can be asumed that bleomycin has only a minor
impact on D. and that this decline is also due to effects of
etoposide and /or cisplatin. As Van Baneveld et al. (1985)
obsered a reduction in D. in patents treated with cisplatin,
vinblastin and bleomycin, it is conceivable that cisplatin is
the major cause of this decline. The reduction in Vc, which
only occurs in patients receiving bleomycin, indicates that
bleomycin does have an effect on the lung vasculature, but
different from the effect ofetoposide and cisplatinL The capil-
lary changes observed usng nailfold capllary microscopic
examination (Bellmunt et al., 1987), the reported cases of
Raynaud's phenomenon (Vogelzang et al., 1981; Adoue et
al., 1984), myocardial infarction (Samuels et al., 1987) and
pulmonary veno-occlusive disease (Joselson et al., 1983)
induced by bleomycin alone or in combination therapy also
suggest direct effects of bleomycin on the vasculature. The
efects of bleomycin occur predominantly in the hlng and
skin vasculature, because these two orgns are, in contrast to
other orgns such as the liver, deficient in bleomycin hydro-
lase which inactivates bleomycin (Ohnuma et al., 1974).
Bleomycin-related alterations of the vasculature are due to
induction of free radials by bleomycin, which causes
endothelal damage, followed by an immunological process
with infiltration of lymphocytes and alveolar macrophages
(Adamson et al., 1974). These cells produce cytokines, which
ILam fncn d duin tr t o tbrculy ancerm*
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further augment cellular accumulation and cause, in com-
bination with bleomycin, proliferation offibroblasts (Moseley
et al., 1986), production of collagen (Otsuka et al., 1978) and
finally fibrosis (Khahl et al., 1989), which may cause occ-
lusion of capillaries, which probably leads to the observed
reduction in Vc in the patients treated with BEP.
Van Barneveld et al. (1985) have shown in patients with
testicular cancer a decline in VC during chemotherapy
consisting of bleomycin, vinblastine and cisplatin. This study
confirms these results, using etoposide instead of vinblastine,
and shows that this decline in VC is specifically caused by
bleomycin, because this effect only occurs in patients treated
with BEP.
The observation that the lung function assessments of the
three patients who developed BIP did not differ significantly
from the other patients receiving BEP does not confirm the
results of Van Barneveld et al. (1985), although three patients
is too small a number to draw conclusions about the usage of
the function tests examined for monitoring BIP.
In conclusion, this study shows that the TWcO, widely used
to monitor the potential lethal pulmonary toxicity induced by
bleomycin as part of a multidrug anti-cancer treatment, is
not a proper parameter for this purpose as it actually might
measure effects of etoposide and cisplatin. Also, changes in
the diffusing capacity of the alveolo-capillary membrane (D.n)
and KO are not specific for detecting bleomycin-induced
toxicity. In contrast, bleomycin induces pulmonary altera-
tions that are specifically reflected in the pulmonary capillary
blood volume (Vc) and vital capacity (VC). These two para-
meters may be the most suitable for determining bleomycin
effects in the lung.
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